Format

Send to

Choose Destination
Cancer Cell. 2015 Jan 12;27(1):12-4. doi: 10.1016/j.ccell.2014.12.004.

Biomarkers in cancer immunotherapy.

Author information

1
Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: t.schumacher@nki.nl.
2
Department of Theoretical Biology and Bioinformatics, Utrecht University, 3584 CH Utrecht, the Netherlands.
3
Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.

Abstract

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.

PMID:
25584891
DOI:
10.1016/j.ccell.2014.12.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center